BRD4
溴尿嘧啶
癌症研究
多发性骨髓瘤
医学
白血病
免疫学
组蛋白
生物
遗传学
基因
作者
Rili Gao,Chengwu Zeng,Yangqiu Li
出处
期刊:Zhongguo shi yan xue ye xue za zhi
日期:2021-08-01
卷期号:29 (4): 1365-1368
标识
DOI:10.19746/j.cnki.issn.1009-2137.2021.04.057
摘要
Bromodomain-containing protein 4 (BRD4) is one of the most important members in the bromodomain and extra terminal domain(BET) family, it plays an important role in cellular physiology in human body, such as cell cycles, cell proliferation, and immune response. Recent studies have shown that BRD4 is associated with occurrence and development of acute myeloblastic leukemia, multiple myeloma and lymphoma. The mechanisms of BRD4 in hematologic malignancies including the regulation of c-Myc expression, and participation of the composition of super-enhancer, etc. At present, many kinds of inhibitors have been developed to target inhibit BRD4 for therapy in hematologic malignancies, and some of BRD4 inhibitors have entered phase Ⅱ clinical trials, which suggested that BRD4 inhibitors are expected to become new therapeutic agents for hematologic malignancies. In this review, the research advance of BRD4 and BRD4 inhibitors in hematologic malignancies was summarized briefly.
科研通智能强力驱动
Strongly Powered by AbleSci AI